ArticleMolecular biology reports2026
Dexpanthenol reduces IL 6 and VEGF gene expression in a rat model of acetic acid induced ulcerative colitis.
Article in Molecular biology reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundUlcerative colitis is a chronic inflammatory bowel disease characterized by inflammation of the colonic mucosa. This study aimed to evaluate the effects of dexpanthenol in an acetic acid-induced model of colitis in rats.
methodsThirty-two adult male Wistar rats were randomly assigned to four groups: Control (intracolonic saline), dexpanthenol, acetic acid (A.A; 4% acetic acid-induced colitis), and treatment (A.A + dexpanthenol 500). Colitis was induced by intracolonic administration of 4% acetic acid. After 7 days, macroscopic and histopathological evaluations of the colon were performed. The mRNA expression levels of IL-6 and VEGF were assessed using real-time PCR. Stool consistency, colon length, and colon weight-to-length ratio were also measured.
resultsDexpanthenol administration significantly ameliorated acetic acid-induced colitis. The A.A + dexpanthenol group showed partial restoration of colon length, improved stool consistency, and a reduced colon weight-to-length ratio compared with the A.A group. Histopathological analysis demonstrated reduced mucosal damage and decreased inflammatory cell infiltration in dexpanthenol-treated rats. In addition, dexpanthenol significantly decreased IL-6 and VEGF mRNA expression compared with the A.A group (P < 0.0001).
conclusionDexpanthenol exerts protective effects against experimental ulcerative colitis in rats by attenuating inflammation, improving tissue integrity, and downregulating IL-6 and VEGF gene expression. These findings suggest its potential as a supportive therapeutic agent in ulcerative colitis.
Indexed as
Identifiers
42084794What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.